Contribute to the fight against COVID-19

The challenge

COVID-19 is an unprecedented public health challenge – but we can beat it by working together. Researchers around the world are working on novel therapeutics and vaccines to treat and prevent COVID-19. However, their work is often hindered:

  • Many laboratories, scientific suppliers, and researchers themselves are in lockdown, or have to adhere to social distancing, preventing them from conducting their life-saving research.
  • Often there is lack of access to specialised equipment and expertise, making it more difficult to do meaningful experiments.
  • Timelines are immensely tight, as the global efforts to halting the spread of SARS-CoV-2 and treating those suffering from COVID-19 must not get delayed.

JAK Inhibitors Deep Profiling Demonstration

Comprehensive dataset on 24 small molecules against the family of Janus kinases​

The Arctoris platform enables accelerated COVID-19 research globally

We offer our robotic platform, state-of-the-art equipment, and full support from our experienced team to assist any researcher in accelerating their COVID-19 research from bench to bedside. To that end, Arctoris has established and validated a set of key assays, including biochemical assays against the SARS-CoV-2 main protease (Mpro), papain-like protease (PLpro), Spike:ACE2 and several others. Arctoris enables researchers to conduct precise therapeutics and vaccine research at the click of a button – fully remotely, even when you and your lab are in lockdown, enabling a broad range of assays to support your work on COVID-19. 

Biochemical Profiling

Human & SARS-CoV-2 targets of relevance to COVID-19
Pricing available on request
  • Human targets: JAK1, JAK2, JAK3, TYK2
  • SARS-CoV-2 targets: Mpro, PLpro, Spike/ACE2 PPI
  • RNA dependent RNA polymerase
  • Mechanistic and kinetic insights

Molecular Assays

SARS-CoV-2 pathogen detection (research purposes only)
Pricing available on request
  • qPCR/digital PCR: SARS CoV-2 nucleic acid detection
  • Gene expression panels >550 genes
  • Elucidate inflammatory & signalling pathways
  • Monitor expression levels of markers

Cellular Assays

Immunoassay solutions for viral research
Pricing available on request
  • Cytokine detection: Lumit™/ELISA
  • Access to primary cells
  • Multiplex cytotoxicity assays
  • Gain insights into immune responses

JAK Inhibitors Deep Profiling Demonstration

Following the announcements that Novartis, Pfizer and Eli Lilly are repurposing JAK inhibitors to treat severe COVID-19, Arctoris has deployed its unique platform to generate comprehensive mechanistic pharmacology for both marketed and research inhibitors against this family of kinases to understand new therapeutic opportunities.

  • Onboarding: 4 target-based assays (JAK1, JAK2, JAK3, and TYK2)
  • Deep mechanistic profiling: 24 small molecule inhibitors (8 marketed, 16 research) against the panel of kinases; fully automated in <10 hours
  • Analysis: 45,848 IC50s and over 1 million data points to give a range of full potency, kinetic and mechanistic insights of the inhibitors
  • Timeline: less than 100 hours in total including 4 new assays developed, optimised & fully automated, and comprehensive datasets generated

Comprehensive biochemical profiling using contact-free picolitre digital dispensing technology & true independent experimentation

JAK2 vs JAK3

Comparative potency, selectivity and kinetic studies against a panel of kinase targets


To find out how to accelerate your project timelines and generate higher quality data, reach out to us today.